Highlights

• Telix Pharmaceuticals Limited (ASX:TLX) received FDA approval for Pixclara.

• The PET imaging drug is used with other evaluations to assess recurrent or progressive glioma.

• The indication covers adults and paediatric patients aged one month and older.

• Pricing, reimbursement and the detailed US rollout remain to be established.

Telix Pharmaceuticals Limited (ASX:TLX) has received US Food and Drug Administration approval for Pixclara, a PET imaging drug used with other evaluations to distinguish recurrent or progressive glioma from treatment-related change. The approval covers adults and paediatric patients aged one month and older.

Telix's growing oncology-imaging portfolio

Telix is an ASX-listed radiopharmaceutical company headquartered in Melbourne. Its Business centres on molecularly targeted radiation products that pair a radioactive isotope with a molecule designed to bind selectively to cancer cells, a model it applies across both diagnostic imaging and, increasingly, therapeutic candidates. Its first commercial success, Illuccix, a PET imaging agent for prostate cancer, is approved in the United States, Canada, Australia, the United Kingdom, Brazil and countries across the European Union. Telix followed with Gozellix, a second-generation prostate-imaging agent that is also FDA-approved. Pixclara extends that model into neuro-oncology, a disease area with considerably fewer approved diagnostic imaging tools than prostate cancer has.

What the FDA approved

Pixclara, known chemically as floretyrosine F 18 or 18F-FET, is a PET radiotracer that targets amino acid transporters, LAT1 and LAT2, which gliomas over-express relative to healthy brain tissue. It helps doctors tell apart tumour regrowth from changes caused by radiotherapy or other treatment, a distinction that is notoriously difficult to make on standard MRI alone. The approval, granted 14 September 2026, covers adults and children from one month old. It followed a Complete Response Letter the FDA issued in April 2025, after which Telix gathered additional data and resubmitted the application in March 2026. The supporting clinical package included 382 patients, 371 adults and 11 children. to FET-PET imaging'.

Why the approval matters commercially

Roughly 24,000 new glioma cases are diagnosed in the United States each year, and gliomas account for about 80 per cent of malignant brain tumours, with a further sizeable share of the roughly 30 per cent of all brain and central nervous system tumours classed as glioma. Until now, US clinicians have relied heavily on MRI and older imaging methods that struggle to separate genuine tumour progression from treatment-related pseudoprogression, a gap that can delay or misdirect subsequent care decisions for patients and their treating oncologists. The approval also extends Telix's pattern of converting early regulatory setbacks into eventual clearances, following a similar complete-response-then-resubmission path to some of its earlier products.

Key Insights

Telix has not disclosed pricing or a detailed US commercial rollout timeline for Pixclara, and reimbursement coverage under Medicare and private insurers will take time to establish nationally across hospitals and imaging centres. A related Phase 3 study is under way to expand Pixclara's use into brain metastases, a substantially larger patient population than primary glioma, but that data has not yet been reported and no completion date has been publicly disclosed. Investors should also note that Telix's broader radiopharmaceutical pipeline still carries ordinary regulatory risk, with other diagnostic and therapeutic candidates still awaiting FDA decisions in the months ahead. For now, Pixclara stands as a validated but early-stage commercial product, with US adoption rates, payer coverage and the metastases trial data the next indicators worth watching closely.